Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

April 24, 2024 updated by: Bristol-Myers Squibb

A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
605

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Expanded Access

Expanded Access

A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved by the U.S. Food and Drug Administration (FDA). Also called compassionate use. There are different expanded access types.
No longer available

No longer available

  • Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
  • No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
  • Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
  • Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
 outside the clinical trial. See expanded access record.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Sydney, New South Wales, Australia, 2139
        • Local Institution - 0032
    • Queensland
      • Birtinya, Queensland, Australia, 4575
        • Local Institution - 0031
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Local Institution - 0033
      • Malvern, Victoria, Australia, 3144
        • Local Institution - 0030
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Local Institution - 0034
  • Belgium
      • Brussels, Belgium, 1090
        • Local Institution - 0089
      • Edegem, Belgium, 2650
        • Local Institution - 0086
      • Liège, Belgium, 4000
        • Local Institution - 0087
      • Sint-Niklaas, Belgium, 9100
        • Local Institution - 0088
  • Brazil
      • Sao Paulo, Brazil, 05403-010
        • Local Institution - 0064
    • Sao Paulo
      • Barretos, Sao Paulo, Brazil, 14784-400
        • Local Institution
  • Chile
    • Metropolitana
      • Santiago, Metropolitana, Chile, 8420383
        • Local Institution - 0018
  • China
      • Kunming, China
        • Local Institution - 0124
      • Shanghai, China, 200030
        • Local Institution - 0120
    • Heilongjiang
      • Harbin Shi, Heilongjiang, China, 150081
        • Local Institution - 0133
    • Jilin
      • Changchun, Jilin, China, 130021
        • Local Institution
    • Liaoning
      • Shenyang, Liaoning, China
        • Local Institution
  • Colombia
      • Bogota, Colombia
        • Local Institution - 0039
      • Bogota, Colombia
        • Local Institution - 0040
  • France
      • Caen, France, 14033
        • Local Institution - 0057
      • Creteil, France, 94010
        • Local Institution - 0073
      • La Tronche, France, 38700
        • Local Institution - 0074
      • Lille Cedex, France, 59037
        • Local Institution - 0067
      • Marseille Cedex 20, France, 13915
        • Local Institution - 0069
      • Paris, France, 75018
        • Local Institution - 0056
      • Saint Herblain, France, 44805
        • Local Institution - 0080
      • Strasbourg Cedex, France, 67091
        • Local Institution - 0093
      • Toulon Cedex, France, 83056
        • Local Institution - 0058
      • Toulouse Cedex 9, France, 31059
        • Local Institution - 0068
  • Germany
      • Cologne, Germany, 51109
        • Local Institution - 0026
      • Coswig, Germany, 01640
        • Local Institution - 0054
      • Essen, Germany, 45147
        • Local Institution - 0038
      • Gottingen, Germany, 37075
        • Local Institution - 0023
      • Grosshansdorf, Germany, 22927
        • Local Institution - 0024
      • Hamburg, Germany, 21075
        • Local Institution - 0027
      • Heidelberg, Germany, 69126
        • Local Institution - 0037
      • Homburg an d. Saar, Germany, 66421
        • Local Institution - 0021
      • Immenhausen, Germany, 34376
        • Local Institution - 0022
      • Moers, Germany, 47441
        • Local Institution - 0019
  • Greece
      • Athens, Greece, 11527
        • Local Institution - 0017
      • Thessaloniki, Greece, 57001
        • Local Institution - 0016
  • Italy
      • Aviano, Italy, 33081
        • Local Institution - 0047
      • Bari, Italy, 70124
        • Local Institution - 0044
      • Catania, Italy, 95124
        • Local Institution - 0046
      • Genova, Italy, 16132
        • Local Institution - 0045
      • Napoli, Italy, 80131
        • Local Institution - 0043
      • Rozzano, Italy, 20089
        • Local Institution - 0048
      • Siena, Italy, 53100
        • Local Institution - 0041
    • Emilia-Romagna
      • Ravenna, Emilia-Romagna, Italy, 48121
        • Local Institution - 0042
  • Japan
      • Osakasayama-city, Japan, 5898511
        • Local Institution - 0113
    • Aichi
      • Nagoya-shi, Aichi, Japan, 4668560
        • Local Institution - 0105
    • Chiba
      • Chiba-shi, Chiba, Japan, 2608677
        • Local Institution - 0097
    • Hiroshima
      • Fukuyama-shi, Hiroshima, Japan, 7200001
        • Local Institution - 0108
      • Hiroshima-Shi, Hiroshima, Japan, 7348551
        • Local Institution - 0114
    • Hokkaido
      • Sapporo-shi, Hokkaido, Japan, 0030804
        • Local Institution - 0101
    • Hyogo
      • Amagasaki-shi, Hyogo, Japan, 6608550
        • Local Institution - 0106
      • Nishinomiya-shi, Hyogo, Japan, 6638501
        • Local Institution - 0098
    • Kanagawa
      • Yokohama-shi, Kanagawa, Japan, 2210855
        • Local Institution - 0095
    • Miyagi
      • Natori-shi, Miyagi, Japan, 9811293
        • Local Institution - 0104
    • Niigata
      • Niigata-shi, Niigata, Japan, 9518520
        • Local Institution - 0107
    • Okayama
      • Okayama-shi, Okayama, Japan, 7028055
        • Local Institution - 0100
    • Saitama
      • Kitaadachi-gun, Saitama, Japan, 3620806
        • Local Institution - 0096
    • Tokyo
      • Chuo-ku, Tokyo, Japan, 1040045
        • Local Institution - 0094
    • Yamaguchi
      • Ube-shi, Yamaguchi, Japan, 7550241
        • Local Institution - 0099
  • Mexico
      • Chihuahua, Mexico, 31000
        • Local Institution - 0118
    • Distrito Federal
      • Df, Distrito Federal, Mexico, 06720
        • Local Institution - 0079
      • Mexico, Distrito Federal, Mexico, 14000
        • Local Institution - 0053
      • Mexico, Distrito Federal, Mexico, 14050
        • Local Institution - 0050
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44270
        • Local Institution - 0051
  • Netherlands
      • Amsterdam, Netherlands, 1066 CX
        • Local Institution - 0092
      • Rotterdam, Netherlands, 3000 CA
        • Local Institution - 0091
  • Poland
      • Bytom, Poland, 41-902
        • Local Institution - 0078
      • Krakow, Poland, 31-202
        • Local Institution - 0076
      • Warszawa, Poland, 02-781
        • Local Institution - 0077
  • Romania
      • Bucharest, Romania, 020122
        • Local Institution - 0115
      • Bucuresti, Romania, 021389
        • Local Institution - 0109
      • Craiova, Romania, 200347
        • Local Institution - 0102
      • Romania, Romania, 400015
        • Local Institution - 0055
  • Russian Federation
      • Moscow, Russian Federation, 115478
        • Local Institution - 0150
      • Moscow, Russian Federation, 121309
        • Local Institution - 0071
      • Saint Petersburg, Russian Federation, 197758
        • Local Institution - 0072
  • South Africa
    • Gauteng
      • Pretoria, Gauteng, South Africa, 0075
        • Local Institution - 0060
    • Western Cape
      • Cape Town, Western Cape, South Africa, 7570
        • Local Institution - 0059
  • Switzerland
      • Bern, Switzerland, 3010
        • Local Institution - 0049
      • Lausanne, Switzerland, 1011
        • Local Institution - 0036
      • Zurich, Switzerland, 8091
        • Local Institution - 0029
  • Turkey
      • Diyarbakır, Turkey, 21280
        • Local Institution - 0111
      • Istanbul, Turkey, 34098
        • Local Institution - 0112
      • Seyhan, Turkey, 01130
        • Local Institution - 0110
  • United Kingdom
      • Leicester, United Kingdom, LE1 5WW
        • Local Institution - 0081
      • London, United Kingdom, EC1A 7BE
        • Local Institution - 0083
      • Manchester, United Kingdom, M23 9LT
        • Local Institution - 0116
      • Southampton, United Kingdom, SO16 6YD
        • Local Institution - 0090
    • Cornwall
      • Truro, Cornwall, United Kingdom, TR1 3LJ
        • Local Institution - 0085
    • Midlothian
      • Edinburgh, Midlothian, United Kingdom, EH4 2XU
        • Local Institution - 0084
  • United States
    • California
      • San Francisco, California, United States, 94143
        • UCSF
    • Connecticut
      • New Haven, Connecticut, United States, 06520
        • Local Institution - 0014
    • Florida
      • Tampa, Florida, United States, 33612
        • H. Lee Moffitt Cancer Center & Research Inst, Inc
    • Illinois
      • Chicago, Illinois, United States, 60637
        • Local Institution - 0002
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • Univ Of Maryland Greenbaum Cancer Center
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Local Institution - 0013
      • Grand Rapids, Michigan, United States, 49503
        • Cancer & Hematology Centers of Western Michigan
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Local Institution - 0004
    • New York
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Nassau
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Local Institution - 0007
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • University of Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15212
        • Allegheny Cancer Center
    • Texas
      • Houston, Texas, United States, 77030
        • Local Institution - 0005
    • West Virginia
      • Morgantown, West Virginia, United States, 26506
        • West Virginia University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Males and Females at least 18 years of age
  • Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
  • ECOG Performance status of 0 or 1
  • Available tumor sample for testing
  • Acceptable blood work

Exclusion Criteria:

  • Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas
  • Prior chemotherapy for pleural mesothelioma
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody
  • History of other malignancy unless the subject has been disease-free for at least 3 years
  • Active, untreated central nervous system (CNS) metastasis

Other protocol defined inclusion/exclusion criteria could apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Nivolumab and Ipilimumab
Specified dose on specified days
Biological: Nivolumab
Other Names:
  • BMS-936558
  • Opdivo
Biological: Ipilimumab
Other Names:
  • BMS-734016
  • Yervoy
Active Comparator: Pemetrexed and Cisplatin (or Carboplatin)
Specified dose on specified days
Drug: Cisplatin
Drug: Pemetrexed
Drug: Carboplatin

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: From randomization to the date of death (Up to 40 Months)
Overall Survival was defined as the time from randomization to the date of death due to any cause. A participant who has not died was censored at last known date alive.
From randomization to the date of death (Up to 40 Months)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR)
Time Frame: From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months)

Objective Response Rate is defined as the percentage of randomized participants who achieve a best overall response of complete response (CR) or partial response (PR) per Blinded Independent Central Review (BICR) assessments. Per adapted m-RECIST for pleural mesothelioma, each single tumor measurement must be at least 10 mm in length to qualify as measureable disease and contribute to the sum that defines the pleural uni-variate measure. Per RECIST 1.1 for solid tumors, confirmation of response required:

CR=Disappearance of all target lesions; PR=At least a 30% decrease in the sum of the Total Tumor Measurement; Progressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement.
From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months)
Disease Control Rate (DCR)
Time Frame: From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months

Disease Control Rate is defined as the percentage of all randomized participants whose Best Overall Response was complete response (CR), partial response (PR), stable disease (SD) or Non-CR/Non-PD as assessed by Blinded Independent Central Review (BICR). Per adapted m-RECIST for pleural mesothelioma, each single tumor measurement must be at least 10 mm in length to qualify as measureable disease and contribute to the sum that defines the pleural uni-variate measure. Per RECIST 1.1 for solid tumors, confirmation of response required:

CR=Disappearance of all target lesions; PR=At least a 30% decrease in the sum of the Total Tumor Measurement; Progressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement; SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Non-CR/Non-PD: Persistence of one or more non-target lesion(s).
From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months
Progression Free Survival (PFS)
Time Frame: From randomization date to the date of first documented tumor progression or death due to any cause, whichever occurs first. (up to 76 months)

Progression Free Survival is defined as the time between the date of randomization and the date of first documented tumor progression per Blinded Independent Central Review (BICR) assessments (using adapted m-RECIST and RECIST 1.1), or death due to any cause, whichever occurs first. Participants who received subsequent anticancer therapy prior to documented progression were censored at the date of the last evaluable tumor assessment conducted on or prior to the date of initiation of the subsequent anticancer therapy.

Progressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement.
From randomization date to the date of first documented tumor progression or death due to any cause, whichever occurs first. (up to 76 months)
Overall Survival (OS) According to PD-L1 Expression Level
Time Frame: From randomization date to the date of death (Up to 76 Months)
PD-L1 Expression is defined as the percent of tumor cells membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is referred to as quantifiable PD-L1 expression and efficacy is determined by overall survival (OS) analysis. OS was defined as the time from randomization to the date of death due to any cause. A participant who has not died was censored at last known date alive.
From randomization date to the date of death (Up to 76 Months)
Progression Free Survival (PFS) According to PD-L1 Expression Level
Time Frame: From randomization date to the date of first documented tumor progression or death due to any cause, whichever occurs first. (up to 76 months)

PD-L1 Expression is defined as the percent of tumor cells membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is referred to as quantifiable PD-L1 expression and efficacy is determined by progression free survival (PFS) analysis. PFS is defined as the time between the date of randomization and the date of first documented tumor progression per Blinded Independent Central Review (BICR) assessments (using adapted m-RECIST and RECIST 1.1), or death due to any cause, whichever occurs first. Participants who received subsequent anticancer therapy prior to documented progression were censored at the date of the last evaluable tumor assessment conducted on or prior to the date of initiation of the subsequent anticancer therapy.

Progressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement.
From randomization date to the date of first documented tumor progression or death due to any cause, whichever occurs first. (up to 76 months)
Objective Response Rate (ORR) According to PD-L1 Expression Level
Time Frame: From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months)

PD-L1 Expression is defined as the percent of tumor cells membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is referred to as quantifiable PD-L1 expression and efficacy is determined by objective response rate (ORR) analysis. ORR is defined as the percentage of participants who achieve a best overall response of complete response (CR) or partial response (PR) per Blinded Independent Central Review (BICR) assessments. Per adapted m-RECIST for pleural mesothelioma, each single tumor measurement must be at least 10 mm in length to qualify as measureable disease and contribute to the sum that defines the pleural uni-variate measure.

per RECIST 1.1 for solid tumors, confirmation of response required: CR=Disappearance of all target lesions; PR=At least a 30% decrease in the sum of the Total Tumor Measurement; Progressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement.
From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Ono Pharmaceutical Co. Ltd

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 29, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 25, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 28, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 31, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 8, 2016

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 14, 2016

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 21, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 24, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CA209-743
  • 2016-001859-43 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mesothelioma

Clinical Trials on Cisplatin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings